FDA Grants Fast Track Designation to Lundbeck's Narcolepsy Drug Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, Lundbeck's investigational orexin 2 receptor agonist, for the treatment of narcolepsy. The drug candidate is currently in Phase 1b development.
VALBY, Denmark – Lundbeck announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, its investigational oral orexin 2 receptor agonist. The designation facilitates the development and expedited review of potential new medicines for serious conditions.
Narcolepsy is a chronic neurological disorder that impairs the brain's ability to regulate sleep and wake cycles. Lu AH69593 targets the orexin 2 receptor, which plays a critical role in the biological pathway regulating wakefulness. This regulatory status is a significant step as Lundbeck advances its portfolio for sleep-wake disorders.
The drug candidate, discovered by Lundbeck, is currently undergoing Phase 1b clinical trials. The Fast Track designation is intended to assist in the development and accelerate the review process for medications addressing unmet medical needs. Lundbeck anticipates close collaboration with the FDA moving forward.
Disruptions in orexin signaling are a known factor in narcolepsy. The development of Lu AH69593 aims to restore wakefulness and sleep-wake regulation for patients, addressing the persistent burden of the disease that current treatments may not fully alleviate.